HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 22, No 11, November 2018 – The Asian Cancer - War on liver cancer       » 2018 Nobel Prize in Physiology or Medicine winners       » Women more prone to selected chemotherapy side effects       » Tibetan fungus could help fight liver cancer       » Standards for TCM decoction to be applied globally       » RMB200 million donation to build Tsinghua University Biomedical Sciences Building      
INSIDE INDUSTRY
New collaboration to speed up cancer drug development
Aims to meet the needs of Asian cancer patients through safe and rational development of targeted cancer drug combinations

A new research collaboration between the National Cancer Centre Singapore (NCCS) and AUM Biosciences, a Singapore headquartered biotechnology company, will aim to develop new potential treatments to battle cancer.

The team plans to shorten the time it would normally take to test and develop new drugs, as well as to introduce safe and effective drug combinations.

The collaboration will combine NCCS’ highly-regarded PDX laboratory model capabilities and knowledge on drug discovery, with AUM Bioscience’s expertise in clinical drug development.

Patient Derived Xenograft (PDX) is the grafting of patients’ tumours onto mice, thereby creating valuable human cancer or PDX models. Different drugs can be tested in these PDX models to evaluate their ability to inhibit tumour growth. Success in these models helps in selecting the suitable drug candidates to put forward for testing in actual patients. It can also help guide the drug development process, including developing a better understanding of how cancers respond to treatment. The PDX models have been extensively used to evaluate novel drugs and develop novel combination therapies for various cancers such as liver, gastric and ovarian cancers.

Currently, a new drug takes 9 to 17 years to develop (pre-clinical stages take 1 to 6 years, clinical phases 1 to 3 take about 6 to 11 years to complete). With this new collaboration, it is estimated that the pre-clinical stage (PDX development and testing) will be shortened to 1.5 to 2 years and the clinical phases (Phase 1 to 3) can be completed in a minimum of 6 to 8 years.

This can potentially help address an unmet medical need faster and more efficiently.

Click here for the complete issue.

NEWS CRUNCH  
news Asia is the fastest growing region for nutraceuticals
news 2018 Nobel Prize in Physiology or Medicine winners
news Vitafoods Asia expands by 40 per cent in 2018
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  

APBN Editorial Calendar 2018
January:
Obesity / Outlook for 2018
February:
Searching for the fountain of youth
March:
Women in Science - Making a difference
April:
Digestive health in the 21st century - Trust your guts
May:
Dental health - The root to good health
June:
Cancer - Therapies and strategies for better patient outcomes
July:
Water management - Technologies for biotech and pharmaceutical industries
August:
Regenerative technology - Meat of the future
September:
Doctor Robot - The digital healthcare revolution
October:
Bones / Breast cancer
November:
Liver health / Top science research nations & institutions
December:
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy